The insulinotropic effect of fluoroquinolones

Biochemical Pharmacology

Volumn 77, Issue 6, 2009, Pages 1040-1052

  Ghaly, Hany ^a   Kriete, Christine ^a   Sahin, Seher ^a   Pflöger, Anja ^a   Holzgrabe, Ulrike ^b   Zünkler, Bernd Joachim ^c   Rustenbeck, Ingo ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Federal Institute for Drugs and Medical Devices   (Germany)

Author keywords

Cytosolic calcium concentration; Fluoroquinolones; Gatifloxacin; Insulin secretion; KATP channel; Plasma membrane potential

Indexed keywords

1 (2 FLUOROPHENYL) 6 FLUOR 1,4 DIHYDRO 4 OXO 7 (2,6 DIMETHYLPIPERAZINE 4 YL) 3 QUINOLINECARBONIC ACID; 1 (2 FLUOROPHENYL) 6 FLUOR 1,4 DIHYDRO 4 OXO 7 (PIPERAZINE 4 YL) 3 QUINOLINECARBONIC ACID; 1 (4 FLUOROPHENYL) 6 FLUOR 1,4 DIHYDRO 4 OXO 7 (2,6 DIMETHYLPIPERAZINE 4 YL) 3 QUINOLINECARBONIC ACID; 1 (4 FLUOROPHENYL) 6 FLUOR 1,4 DIHYDRO 4 OXO 7 (PIPERAZINE 4 YL) 3 QUINOLINECARBONIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ION; CIPROFLOXACIN; DIAZOXIDE; EFAROXAN; GATIFLOXACIN; GLUCOSE; INSULIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLONE DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CALCIUM CELL LEVEL; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PATCH CLAMP; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CELLS, CULTURED; CYTOSOL; FLUOROQUINOLONES; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, KNOCKOUT; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; UP-REGULATION;

EID: 60649096669     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.11.019     Document Type: Article

References (41)

1. Park-Wyllie L.Y., Juurlink D., Kopp A., Shah B.R., Stukel T., Stumpo C., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 (2006) 1-10
2. Frothingham R. Glucose homeostasis abnormalities associated with the use of gatifloxacin. Clin Infect Dis 41 (2005) 1269-1276
3. Roberge R.J., Kaplan R., Frank P., and Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycaemia. Ann Emerg Med 36 (2000) 160-163
4. Menzies D.J., Dorsainvil P.A., Cunha B.A., and Johnson D.H. Severe and persistent hypoglycaemia due to gatifloxacin interaction with oral hypoglycaemic agents. Am J Med 113 (2002) 232-234
5. Bhasin R., Arce F.C., and Pasmantier R. Hypoglycemia associated with the use of gatifloxacin. Am J Med Sci 330 (2005) 250-253
6. Mohr J.F., McKinnon P.S., Peymann P.J., Kenton I., Septimus E., and Okhuysen P.C. A retrospective comparative evaluation of dyglycemias in hospitalized patients receiving gatifloxacin, levofloxacin ciprofloxacin and ceftriaxone. Pharmacotherapy 25 (2005) 1303-1309
7. Maeda N., Tamgawa T., Niki I., Miura H., Ozawa K., and Watanabe G. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 117 (1996) 372-376
8. Ashcroft F.M., and Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 54 (1990) 87-143
9. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49 (2000) 1751-1760
10. + channels. Life Sci 73 (2003) 429-435
11. + channels. Eur J Pharmacol 497 (2004) 111-117
12. ATP channels. Ann Rev Physiol 60 (1998) 667-687
13. Haruhara N., Niwa H., Kitayama S., and Sakai N. Two cases of drug-induced hypoglycemic coma. J Tomakomai City Hospital 14 (2000) 41-46
14. Friedrich L.V., and Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 24 (2004) 1807-1812
15. Beste L.A., and Mersfelder T.L. Hyperglycemia and gatifloxacin: a case report and summary of current literature. Am J Geriatr Pharmacother 3 (2005) 262-265
16. Blommel A.L., and Lutes R.A. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 39 (2005) 1349-1352
17. Tomita T., Onishi M., Kimura Y., and Kihira K. Gatifloxacin induces insulin release and intracellular insulin secretion pancreatic islet cells. Biol Pharm Bull 30 (2007) 644-647
18. Jürgens J., Schedletzky H., Heisig P., Seydel J.K., Wiedemann B., and Holzgrabe U. Synthesis and biological activities of new N1-aryl substituted quinolone antibacterials. Arch Pharm Pharm Med Chem 329 (1996) 179-190
19. +-currents in isolated mouse pancreatic beta-cells. FEBS Lett 261 (1990) 187-190
20. +-channels from pancreatic B-cells. FEBS Lett 239 (1988) 241-244
21. Henquin J.C. A minimum of fuel is necessary for tolbutamide to mimic the effects of glucose on electrical activity in pancreatic β-cells. Endocrinology 139 (1998) 993-998
22. Panten U., Zünkler B.J., Scheit S., Kirchhoff K., and Lenzen S. regulation of energy metabolism in pancreatic islets by glucose and tolbutamide. Diabetologia 29 (1986) 648-654
23. Gajjar D.A., Lacreta F.P., Kollia G.D., Stolz R.R., Berger S., Smith W.B., et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with non insulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 20 (2000) 76S-86S
24. Gajjar D.A., Lacreta F.P., Uderman H.D., Kollia G.D., Duncan G., Birkhofer M.J., et al. A dose-escalation study of the safety, tolerability and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 20 (2000) 49S-58S
25. ATP channel-independent regulation of insulin secretion. J Biol Chem 275 (2000) 9270-9277
26. Yamada C., Nagashima K., Takahashi A., Ueno H., Kawasaki Y., Yamada Y., et al. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 553 (2006) 67-72
27. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 63 (2002) 1921-1935
28. + channels. Toxicology 228 (2006) 239-248
29. ATP channel-blocking effect of imidazolines; A comparison of the effect of efaroxan and its imidazole analogue, KU14R. Diabetologia 48 (2005) 2567-2575
30. Strauss U., Herbrik M., Mix M., Schubert R., and Rolfs A. Whole-cell patch clamp: true perforated or spontaneous conventional recordings?. Pflügers Arch - Eur J Physiol 442 (2001) 634-638
31. Wienbergen A., Bleck C., Grosse Lackmann T., and Rustenbeck I. Antagonism of the insulinotropic action of first generation imidazolines. Biochem Pharmacol 73 (2007) 94-102
32. Idowu O., and Peggins J.O. Simple, rapid determination of enrofloxacin and ciprofloxain in bovine milk and plasma by HPLC with fluorescence detection. J Pharm Biomed Anal 35 (2004) 143-153
33. 2+ oscillations in glucose-stimulated pancreatic β-cells. Am J Physiol 276 (1999) E512-E518
34. Nenquin M., Szollosi A., Aguilar-Bryan L., Bryan J., and Henquin J.C. Both triggering and amplifying pathways contribute to fuel-induced insulin secretion in the absence of sulfonylurea receptor-1 in pancreatic beta-cells. J Biol Chem 279 (2004) 32316-32324
35. 2+ influx. Diabetes 46 (1997) 1305-1311
36. Van Bambeke F., Michot J.M., Van Eldere J., and Tulkens P.M. Quinolones in 2005: an update. Clin Microbiol Infect 11 (2005) 256-280
37. Lode H. Evidence of different profiles of side effects and drug-drug-interactions among the quinolones - the pharmacokinetic standpoint. Chemotherapy 47 suppl 3 (2001) 24-31
38. Khovidunkit W., and Sunthornyothin S. Hypoglycemia, Hyperglycemia, and Gatifloxacin. Ann Intern Med 12 (2004) 966-969
39. Ishiwata Y., Sanada Y., and Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats. Biol Pharm Bull 29 (2006) 527-531
40. LaPlante K.L., Mersfelder T.L., Ward K., and Quilliam B.J. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy 28 (2008) 82-89
41. Holzgrabe U., and Steinert M. N1-phenyl substituted 4-quinolones of tuberculostatic activity. Pharmazie 56 (2001) 850-851